Rating is available when the video has been rented.
This feature is not available right now. Please try again later.
Published on Dec 19, 2014
Dr. Jeffrey Zonder (Karmanos Cancer Institute, Wayne State University, Detroit, Michigan) discusses results from a phase I clinical trial of pomalidomide (Pomalyst/ Imnovid), bortezomib (Velcade), and dexamethasone as initial treatment of AL amyloidosis and light chain deposition disease. These phase I study results were presented at the 56th American Society of Hematology (ASH) Annual Meeting. ASH 2014 abstract 4746.
Please subscribe to our channel! Subscribe to International Myeloma Foundation: http://bit.ly/XlUtPE